GLOW

GLOW is a blend researchers use for skin regeneration and general tissue healing: it combines three peptides in one vial, GHK-cu (a copper-tripeptide, the largest share, used for collagen and skin), BPC-157 (for connective-tissue repair), and TB-500 (for cell migration and remodeling), and it's essentially KLOW without the KPV component. It is not an FDA-approved product, and the combination itself has never been studied in clinical trials, so the blend's effect rests on each component's separate, individually limited evidence plus research-community experience, not proof that combining them adds benefit.

GLOW is marketed for skin regeneration and general recovery, as a fixed blend of GHK-cu, BPC-157, and TB-500. It has never been studied as a combination in clinical trials, so there is no randomized evidence for the blend itself. Its rationale rests on the separate, individually limited evidence bases of its components plus research-community experience, so the combined effect should be read as unproven.

Not FDA approved as a blend (GLOW is a compounded research-peptide formulation; no FDA-approved GLOW product exists). Components have varying individual regulatory status (see component cross-references). Not listed as a blend in the WADA 2026 Prohibited List, but two of the three components are WADA-prohibited: BPC-157 is listed under WADA S0 (Non-Approved Substances), prohibited at all times and explicitly named; TB-500 (thymosin β4 derivatives) is listed under WADA S2.3 (Growth Factors). FDA 503A status (updated 2026-09-03): BPC-157 and TB-500 were removed from the 503A bulks list Category 2 in April 2026 — a transitional gray area, not approval — and were voted on at the Pharmacy Compounding Advisory Committee (PCAC) meeting held July 23, 2026, with FDA's own briefing document proposing that neither be included. FDA has published no summary minutes, vote results, or determination from that meeting as of 2026-09-03, and a PCAC recommendation is advisory and non-binding; neither is on the 503A Bulks List. GHK-cu's 503A nomination was withdrawn in April 2026 and sits on a separate PCAC track scheduled for February 2027. Researchers competing in WADA-tested sport should treat GLOW as containing prohibited components and should not use it. GLOW is essentially KLOW without the KPV component — same three-peptide healing/regeneration core (GHK-cu + BPC-157 + TB-500) without the α-MSH-derived anti-inflammatory tripeptide.

GLOW is a compounded blend with no FDA-approved product. Its compounding status is unsettled: BPC-157 and TB-500 were removed from the FDA 503A bulks list Category 2 in April 2026 (a transitional gray area, not approval) and were reviewed by an FDA advisory committee on July 23, 2026, with FDA proposing against inclusion; no FDA determination has been issued; GHK-cu's nomination was withdrawn and is on a separate review track (February 2027). Two components are banned in WADA-tested sport — BPC-157 (S0, prohibited at all times) and TB-500 (S2.3) — so athletes should not use it. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. GLOW is a compounded research-peptide blend; no FDA-approved GLOW product exists. Information in this entry is informational, not medical advice. Always confirm dose calculations and consult appropriate professional guidance before any protocol decisions.

⚠️ Composition reflects the most-cited research-community GLOW formulation ( total per vial). The canonical GLOW blend formulation referenced across multiple research-peptide vendors and compounding-pharmacy sources is: GHK-cu + BPC-157 + TB-500 = total per vial. GLOW is essentially KLOW minus KPV — same three-peptide healing/regeneration core without the α-MSH-derived anti-inflammatory tripeptide. Some GLOW formulations vary (different total weights, different ratios, occasional component substitutions). Researchers should confirm the specific formulation of their actual product against the vial label and Certificate of Analysis before using this entry's dosing math. Component cross-references: [GHK-cu](./ghk-cu.md), [BPC-157](./bpc-157.md), [TB-500](./tb-500.md). For comparison: [KLOW](./klow.md) covers the four-component variant with KPV.

⚠️ Mismatched-range blend — same dosing-tradeoff framing as KLOW. Per the blend taxonomy established for the [BPC-157/TB-500 blend entry](./bpc-157-tb-500-blend.md) and inherited by KLOW, GLOW is a mismatched-range blend — the three components have meaningfully different typical research-community dose ranges (GHK-cu ~; BPC-157 ~; TB-500 ~). At the canonical per-vial ratio, dosing decisions for GLOW require accepting that at least some component will be outside its standalone "ideal" range at any given total-blend dose. Researchers should be explicit about which component they are prioritizing dosing-wise.

⚠️ Component-level WADA and FDA caveats compound across the blend. Same regulatory situation as KLOW. WADA: BPC-157 is listed under S0 (Non-Approved Substances), prohibited at all times and explicitly named on the 2026 Prohibited List; TB-500 is listed under S2.3 (Growth Factors). A blend inherits its most restrictive component, so GLOW is unambiguously prohibited in WADA-tested sport. FDA 503A (as of 2026-07-18): BPC-157 and TB-500 were removed from 503A bulks list Category 2 in April 2026 — this is a transitional gray area, not approval and not a green light to compound — and were voted on at the PCAC meeting held July 23, 2026, with FDA briefing materials proposing against their addition; FDA has published no minutes, vote results, or determination as of 2026-09-03, and a PCAC recommendation is advisory and non-binding. GHK-cu is on a separate track: its 503A nomination was withdrawn in April 2026, with PCAC review scheduled for February 2027. GLOW therefore inherits these unresolved regulatory complications and should not be used by athletes in WADA-tested sport.

GLOW is a research-community compounded peptide blend combining three research peptides — GHK-cu, BPC-157, and TB-500 — into a single lyophilized formulation. The blend is marketed primarily for skin regeneration and anti-aging, with secondary positioning for general tissue healing and recovery. The "GLOW" branding refers to the cosmetic / skin-regeneration positioning that distinguishes GLOW from the broader-anti-inflammatory KLOW formulation (which includes KPV).

Component-level rationale: - GHK-cu (the largest component) — copper-tripeptide complex; primary contributor to the blend's collagen synthesis, skin-firmness, hair-regrowth, and anti-aging effects.[¹] - BPC-157 — gastric-juice-derived peptide fragment; primary contributor to angiogenesis and tendon/ligament repair effects. - TB-500 — thymosin β4-derived fragment; primary contributor to cell migration and tissue remodeling effects.

Mechanism — three complementary tissue-regeneration mechanisms. The GLOW formulation rationale is that the three components target distinct but complementary aspects of tissue regeneration: - GHK-cu drives collagen synthesis and gene-expression modulation. - BPC-157 promotes angiogenesis and connective tissue repair. - TB-500 supports cell migration during tissue remodeling.

The combined effect is theoretically broader than any single component for tissue-regeneration applications. The combined effect is not characterized in published clinical literature — GLOW has not been studied as a fixed combination in RCTs.

GLOW vs KLOW. GLOW (3 components) and KLOW (4 components) share the same GHK-cu/BPC-157/TB-500 core; KLOW adds KPV for an additional anti-inflammatory mechanism. Researchers should choose between GLOW and KLOW based on whether the KPV addition is relevant to the indication: - GLOW is positioned for skin/cosmetic and tissue-regeneration indications where the KPV anti-inflammatory mechanism is not the primary need - KLOW is positioned for indications where inflammatory cytokine reduction is also a goal (combined healing + anti-inflammatory)

Common research interests. GLOW's research-community use spans: - Skin regeneration and anti-aging (cosmetic-focused) — the dominant rationale, leveraging GHK-cu's collagen-synthesis effects supplemented by BPC-157 and TB-500 healing contributions - Hair regrowth — driven primarily by the GHK-cu component (parallel to topical GHK-cu hair regrowth research) - Tissue regeneration / general recovery — broader healing applications - Athletic recovery — research-community use for training recovery

Regulatory status. Same as KLOW: no FDA-approved GLOW product exists, and the blend's regulatory status inherits from its components — which sit on two different FDA tracks, so they should not be described together:

- BPC-157 and TB-500 — removed from the FDA 503A bulks list Category 2 in April 2026. Removal is not approval; it moves them into a transitional gray area pending formal evaluation. Both were on the PCAC agenda for July 23–24, 2026, and FDA briefing materials propose against adding them. That meeting took place on July 23, 2026 and the committee voted on both. FDA has published no summary minutes, vote results, or final determination from that meeting as of 2026-09-03, and a PCAC recommendation is advisory and non-binding — panel review → FDA determination still pending → 503A compounding not permitted on that basis — neither is on the 503A Bulks List. - GHK-cu — 503A nomination withdrawn in April 2026; scheduled for a separate PCAC review in February 2027. It is *not* part of the July 2026 docket. - WADA — BPC-157 is S0 (Non-Approved Substances), prohibited at all times; TB-500 is S2.3 (Growth Factors). GHK-cu is not explicitly listed. Under the most-restrictive-component rule, GLOW is prohibited in WADA-tested sport on two independent grounds.

Researchers in WADA-tested sport should not use GLOW.

Commonly reported

• Combined angiogenic activity. Both BPC-157 and GHK-cu have angiogenic effects; combined effect may be additive. Theoretical contraindication for active or undiagnosed malignancy applies.
• Injection site reactions — common across all three components.
• Mild flushing or warmth post-injection — uncommon.
• Generally well-tolerated in research-community reports at typical doses.

Active malignancy or undiagnosed cancer concern — caution; angiogenic and gene-expression-modulating activity across multiple components

Wilson disease or copper metabolism disorders — strongly contraindicated due to GHK-cu copper content

Pregnancy and lactation: no data; default to contraindicated

Pediatric use: no data — should not be used in researchers under 18

Regulatory note (US): BPC-157 and TB-500 were removed from the FDA 503A bulks list Category 2 in April 2026 — a transitional gray area, not approval — and were voted on at the PCAC meeting held July 23, 2026 with FDA proposing against their addition; FDA has published no minutes, vote results, or determination as of 2026-09-03, and a PCAC recommendation is advisory and non-binding. GHK-cu's nomination was withdrawn in April 2026 and is set for a separate PCAC review in February 2027. No component, and no GLOW blend product, is FDA-approved.

Regulatory note (WADA): BPC-157 is listed under WADA S0 (Non-Approved Substances), prohibited at all times. TB-500 (thymosin β4 derivatives) is listed under WADA S2.3 (Growth Factors). Researchers in WADA-tested sport should not use GLOW.

Peptide blend

A combination of two or more peptides prepared together in a single formulation.

Peptide

A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.

Subcutaneous

An injection into the fatty layer just under the skin, rather than into a muscle or vein.

Compounding pharmacy

a pharmacy that prepares a medication to order under a prescription.

1. Component-level citations apply via the cross-referenced standalone entries: GHK-cu, BPC-157, TB-500. The GLOW blend has not been studied as a fixed combination in published RCTs; this entry's citations are inherited from the component standalone entries. A literature search for the combination returned no results — there is no GLOW blend study to cite. Representative component citations spot-verified live against
2. Research-community vendor formulation references — GLOW is sold by multiple research-peptide vendors with the canonical formulation (BioLongevityLabs, Rejuvatide Peptides, MedShiftRx, Revolution Health & Wellness, others). These are marketing/vendor sources, not scientific evidence — they establish only how the blend is commonly sold, and support no claim beyond formulation provenance. if ever cited for anything further. Vendor formulations should be confirmed against the specific product Certificate of Analysis.
3. WADA listings and FDA 503A status — re-derived from the refreshed component entries, not maintained in parallel. WADA (2026 Prohibited List, in force): BPC-157 is listed under S0 (Non-Approved Substances), prohibited at all times and explicitly named ("…including but not limited to BPC-157…"); TB-500 / thymosin β4 derivatives are listed under S2.3 (Growth Factors). GHK-cu is not explicitly listed. See BPC-157 for the S0 citation and TB-500 for the S2.3 citation. The 2027 Prohibited List publishes ~September–October 2026 — re-verify then. before any 2027-cycle use. FDA 503A: BPC-157 (free base + acetate) and TB-500 (free base + acetate) were removed from 503A bulks list Category 2 in April 2026 (part of a removal of ~12 peptides). Removal is not approval — it moves them out of the "significant safety risks" bucket into a transitional status pending formal evaluation. Both were on the Pharmacy Compounding Advisory Committee agenda for July 23–24, 2026 and were voted on at that meeting; FDA briefing materials proposed against adding them. FDA has published no minutes, vote results, or determination as of 2026-09-03, and a PCAC recommendation is advisory and non-binding. FDA notice: July 23–24, 2026 PCAC meeting. The meeting has taken place, but FDA has issued no determination — the outcome is still pending, not a decision. GHK-cu is on a separate track: its 503A nomination was withdrawn in April 2026, with PCAC review scheduled for February 2027. See GHK-cu, BPC-157, TB-500 for the component-level citations.

• CJC-1295 — discussed together in this entry's stacks section
• Tesamorelin — discussed together in this entry's stacks section
• NAD+ — discussed together in this entry's stacks section
• ARA-290 — same mechanism class
• BPC-157 / TB-500 Blend — same mechanism class
• BPC-157 — same mechanism class